Back to Search
Start Over
Cost-effectiveness of response evaluation after chemoradiation in patients with advanced oropharyngeal cancer using 18F-FDG-PET-CT and/or diffusion-weighted MRI
- Source :
- BMC Cancer, 17(1):256. BioMed Central, BMC Cancer, 17. BioMed Central, BMC Cancer, BMC Cancer, Vol 17, Iss 1, Pp 1-9 (2017), BMC Cancer, 17, Greuter, M J E, Schouten, C S, Castelijns, J A, de Graaf, P, Comans, E F I, Hoekstra, O S, de Bree, R & Coupé, V M H 2017, ' Cost-effectiveness of response evaluation after chemoradiation in patients with advanced oropharyngeal cancer using 18 F-FDG-PET-CT and/or diffusion-weighted MRI ', BMC Cancer, vol. 17, no. 1, 256 . https://doi.org/10.1186/s12885-017-3254-0
- Publication Year :
- 2017
-
Abstract
- Contains fulltext : 174260.pdf (Publisher’s version ) (Open Access) BACKGROUND: Considerable variation exists in diagnostic tests used for local response evaluation after chemoradiation in patients with advanced oropharyngeal cancer. The yield of invasive examination under general anesthesia (EUA) with biopsies in all patients is low and it may induce substantial morbidity. We explored four response evaluation strategies to detect local residual disease in terms of diagnostic accuracy and cost-effectiveness. METHODS: We built a decision-analytic model using trial data of forty-six patients and scientific literature. We estimated for four strategies the proportion of correct diagnoses, costs concerning diagnostic instruments and the proportion of unnecessary EUA indications. Besides a reference strategy, i.e. EUA for all patients, we considered three imaging strategies consisting of 18FDG-PET-CT, diffusion-weighted MRI (DW-MRI), or both 18FDG-PET-CT and DW-MRI followed by EUA after a positive test. The impact of uncertainty was assessed in sensitivity analyses. RESULTS: The EUA strategy led to 96% correct diagnoses. Expected costs were euro468 per patient whereas 89% of EUA indications were unnecessary. The DW-MRI strategy was the least costly strategy, but also led to the lowest proportion of correct diagnoses, i.e. 93%. The PET-CT strategy and combined imaging strategy were dominated by the EUA strategy due to respectively a smaller or equal proportion of correct diagnoses, at higher costs. However, the combination of PET-CT and DW-MRI had the highest sensitivity. All imaging strategies considerably reduced (unnecessary) EUA indications and its associated burden compared to the EUA strategy. CONCLUSIONS: Because the combined PET-CT and DW-MRI strategy costs only an additional euro927 per patient, it is preferred over immediate EUA since it reaches the same diagnostic accuracy in detecting local residual disease while leading to substantially less unnecessary EUA indications. However, if healthcare resources are limited, DW-MRI is the strategy of choice because of lower costs while still providing a large reduction in unnecessary EUA indications.
- Subjects :
- Adult
18F-FDG-PET-CT
Cancer Research
medicine.medical_specialty
Cost effectiveness
Cost-Benefit Analysis
Diffusion-weighted MRI
lcsh:RC254-282
Multimodal Imaging
030218 nuclear medicine & medical imaging
03 medical and health sciences
0302 clinical medicine
Fluorodeoxyglucose F18
Positron Emission Tomography Computed Tomography
Genetics
medicine
Journal Article
Humans
In patient
Medical diagnosis
Aged
Neoplasm Staging
Oropharyngeal cancer
Cost–benefit analysis
business.industry
Cancer
Chemoradiotherapy
Middle Aged
medicine.disease
lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Prognosis
3. Good health
Surgery
Oropharyngeal Neoplasms
Diffusion Magnetic Resonance Imaging
Oncology
030220 oncology & carcinogenesis
Response evaluation
Fdg pet ct
Female
Cost-effectiveness
Radiology
Radiopharmaceuticals
business
Diffusion MRI
Rare cancers Radboud Institute for Health Sciences [Radboudumc 9]
Research Article
Follow-Up Studies
Subjects
Details
- Language :
- English
- ISSN :
- 14712407
- Database :
- OpenAIRE
- Journal :
- BMC Cancer, 17(1):256. BioMed Central, BMC Cancer, 17. BioMed Central, BMC Cancer, BMC Cancer, Vol 17, Iss 1, Pp 1-9 (2017), BMC Cancer, 17, Greuter, M J E, Schouten, C S, Castelijns, J A, de Graaf, P, Comans, E F I, Hoekstra, O S, de Bree, R & Coupé, V M H 2017, ' Cost-effectiveness of response evaluation after chemoradiation in patients with advanced oropharyngeal cancer using 18 F-FDG-PET-CT and/or diffusion-weighted MRI ', BMC Cancer, vol. 17, no. 1, 256 . https://doi.org/10.1186/s12885-017-3254-0
- Accession number :
- edsair.doi.dedup.....141944df08c456aad4ce4e62f8636474